JP2004505068A - 非ステロイド性抗炎症剤 - Google Patents

非ステロイド性抗炎症剤 Download PDF

Info

Publication number
JP2004505068A
JP2004505068A JP2002515874A JP2002515874A JP2004505068A JP 2004505068 A JP2004505068 A JP 2004505068A JP 2002515874 A JP2002515874 A JP 2002515874A JP 2002515874 A JP2002515874 A JP 2002515874A JP 2004505068 A JP2004505068 A JP 2004505068A
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
benzoxazin
amino
trifluoromethylvaleroylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002515874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505068A5 (enExample
Inventor
ヤロホ，ステファン
レーマン，マンフレート
シュメース，ノルベルト
ブーフマン，ベルント
レービンケル，ハルトムート
ドロエシャー，ペーター
スクバラ，ベルナー
クロリキービクツ，コンラート
ヘネケス，ハルトビク
シェーケ，ハイケ
ショッテリウス，アルント
Original Assignee
シエーリング　アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シエーリング　アクチエンゲゼルシャフト filed Critical シエーリング　アクチエンゲゼルシャフト
Publication of JP2004505068A publication Critical patent/JP2004505068A/ja
Publication of JP2004505068A5 publication Critical patent/JP2004505068A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002515874A 2000-07-28 2001-07-23 非ステロイド性抗炎症剤 Withdrawn JP2004505068A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10038639A DE10038639A1 (de) 2000-07-28 2000-07-28 Nichtsteroidale Entzündungshemmer
PCT/EP2001/008501 WO2002010143A1 (de) 2000-07-28 2001-07-23 Nichtsteroidale entzündungshemmer

Publications (2)

Publication Number Publication Date
JP2004505068A true JP2004505068A (ja) 2004-02-19
JP2004505068A5 JP2004505068A5 (enExample) 2008-09-11

Family

ID=7651697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515874A Withdrawn JP2004505068A (ja) 2000-07-28 2001-07-23 非ステロイド性抗炎症剤

Country Status (27)

Country Link
US (3) US6777409B2 (enExample)
EP (1) EP1309571A1 (enExample)
JP (1) JP2004505068A (enExample)
KR (1) KR20030019626A (enExample)
CN (2) CN1444570A (enExample)
AU (2) AU8200901A (enExample)
BG (1) BG107488A (enExample)
BR (1) BR0112786A (enExample)
CA (1) CA2417444A1 (enExample)
CZ (1) CZ2003216A3 (enExample)
DE (1) DE10038639A1 (enExample)
EA (1) EA005926B1 (enExample)
EE (1) EE200300043A (enExample)
HR (1) HRP20030148A2 (enExample)
HU (1) HUP0301344A3 (enExample)
IL (1) IL154143A0 (enExample)
MX (1) MXPA02012933A (enExample)
NO (1) NO20030406L (enExample)
NZ (1) NZ523822A (enExample)
PE (1) PE20020230A1 (enExample)
PL (1) PL366336A1 (enExample)
SK (1) SK812003A3 (enExample)
TW (1) TWI282336B (enExample)
UA (1) UA77657C2 (enExample)
WO (1) WO2002010143A1 (enExample)
YU (1) YU5503A (enExample)
ZA (1) ZA200301639B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213674A (ja) * 2005-02-07 2006-08-17 Ube Ind Ltd ４−ホルミルテトラヒドロピラン化合物の製法
JP2006265173A (ja) * 2005-03-24 2006-10-05 Sumitomo Chemical Co Ltd グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶
JP2009518353A (ja) * 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症剤としてのグルココルチコイド受容体モジュレーター
JP2009518352A (ja) * 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症性剤としてのプロピオンアミド化合物
JP2009534353A (ja) * 2006-04-20 2009-09-24 グラクソ グループ リミテッド 新規化合物

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238707B2 (en) 2000-07-28 2007-07-03 Schering Ag Substituted pentanols, a process for their production and their use as anti-inflammatory agents
DE10346940B3 (de) * 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
DE60309829T2 (de) 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
EP1344776A1 (en) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
MXPA04008881A (es) * 2002-03-11 2004-12-07 Schering Ag 5-{2- hidroxi-3 -[1-(3- trifluorometilfenil) -ciclopropil] -propionilamino}- ftalida y compuestos relacionados con actividad que modula el receptor de progesterona para utilizarse en control de fertilidad y terapia de reemplazo hormonal.
UA80120C2 (en) * 2002-03-26 2007-08-27 Boehringer Ingelheim Pharma Glucocorticoid mimetics, pharmaceutical composition based thereon
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) * 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR20050036982A (ko) * 2002-08-29 2005-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체
JP4373926B2 (ja) 2003-01-03 2009-11-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド １−プロパノール及び１−プロピルアミン誘導体ならびにグルココルチコイドリガンドとしての使用
WO2004071389A2 (en) * 2003-02-15 2004-08-26 Glaxo Group Limited Non-steroidal infalmmation inhibitors
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
WO2005003098A1 (de) * 2003-07-01 2005-01-13 Schering Aktiengesellschaft Heterozyklisch substituierte pentanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
DE102004017662B3 (de) * 2004-04-05 2005-12-08 Schering Ag Mehrfach substituierte Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
RS20060250A (sr) 2003-10-08 2008-08-07 Schering Aktiengesellschaft, Derivati tetrahidronaftalena, postupak njihove proizvodnje i njihova upotreba kao anti-inflamatornih sredstava
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE10347385A1 (de) * 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7507843B2 (en) 2003-10-16 2009-03-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006000401A1 (en) * 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) * 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
DE102004044680B3 (de) * 2004-09-09 2006-06-08 Schering Ag Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
US20060084652A1 (en) * 2004-09-09 2006-04-20 Stefan Baeurle Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20060167025A1 (en) * 2004-12-22 2006-07-27 Markus Berger Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
DE102004063227A1 (de) * 2004-12-22 2006-07-06 Schering Ag Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
ES2326907T3 (es) 2004-12-27 2009-10-21 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
DE102005014089A1 (de) * 2005-03-22 2006-09-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US20060229305A1 (en) * 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE102005017301A1 (de) * 2005-04-14 2006-10-19 Schering Ag Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005017286B3 (de) * 2005-04-14 2006-12-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005017326A1 (de) * 2005-04-14 2007-03-29 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102005018026B4 (de) * 2005-04-14 2006-12-21 Schering Ag Substituierte Styrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
BRPI0608221A2 (pt) 2005-04-29 2009-11-24 Wyeth Corp métodos para preparação de um composto, e para preparar seletivamente um composto de nitrila, e, composto
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7408060B2 (en) * 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1834948A1 (de) * 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
AU2007241343B2 (en) 2006-04-21 2011-09-01 Novartis Ag Purine derivatives for use as adenosin A2A receptor agonists
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
MX2009005264A (es) 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP1958934A1 (en) * 2007-02-16 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents
PT2155721E (pt) 2007-05-07 2011-05-09 Novartis Ag Compostos org?nicos
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
EP2062880A1 (en) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
DK2300472T3 (da) 2008-06-06 2012-04-10 Boehringer Ingelheim Int Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
EP2149558A1 (en) 2008-07-21 2010-02-03 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
EP2379507B1 (en) 2008-12-30 2013-10-16 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP2013500962A (ja) 2009-07-31 2013-01-10 カディラ ヘルスケア リミティド グルココルチコイド受容体のモジュレーターとしての新規化合物
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
HK1203378A1 (en) 2011-11-23 2015-10-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
RU2483723C1 (ru) * 2012-04-25 2013-06-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения эндокринной офтальмопатии
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2014198909A1 (en) 2013-06-14 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
JP6754533B2 (ja) 2015-03-30 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
AU2017210156B2 (en) 2016-01-19 2021-10-28 Corcept Therapeutics, Inc. Differential diagnosis of Ectopic Cushing's Syndrome
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
CN110520121B (zh) 2017-03-31 2023-07-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂治疗宫颈癌
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
US20190151283A1 (en) * 2017-10-27 2019-05-23 Association Pour La Recherche À L'igbmc (Ari) NON-STEROIDAL SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTIC MODULATORS (SEGRAMs) AND USES THEREOF
EP3569228A1 (en) * 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
JP2024500748A (ja) 2020-12-18 2024-01-10 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19856475A1 (de) 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
JP3464405B2 (ja) * 1999-02-18 2003-11-10 阪神化成工業株式会社 多層薄肉容器

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213674A (ja) * 2005-02-07 2006-08-17 Ube Ind Ltd ４−ホルミルテトラヒドロピラン化合物の製法
JP2006265173A (ja) * 2005-03-24 2006-10-05 Sumitomo Chemical Co Ltd グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶
JP2009518353A (ja) * 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症剤としてのグルココルチコイド受容体モジュレーター
JP2009518352A (ja) * 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症性剤としてのプロピオンアミド化合物
JP2009534353A (ja) * 2006-04-20 2009-09-24 グラクソ グループ リミテッド 新規化合物

Also Published As

Publication number Publication date
WO2002010143A1 (de) 2002-02-07
HUP0301344A2 (hu) 2003-08-28
AU2001282009B2 (en) 2006-06-22
US20020077356A1 (en) 2002-06-20
US20040254249A1 (en) 2004-12-16
EA005926B1 (ru) 2005-08-25
DE10038639A1 (de) 2002-02-21
MXPA02012933A (es) 2003-09-22
UA77657C2 (en) 2007-01-15
US20060040933A1 (en) 2006-02-23
NO20030406D0 (no) 2003-01-27
CZ2003216A3 (cs) 2003-05-14
ZA200301639B (en) 2004-06-22
US7166592B2 (en) 2007-01-23
US6777409B2 (en) 2004-08-17
AU8200901A (en) 2002-02-13
PE20020230A1 (es) 2002-03-17
BR0112786A (pt) 2003-07-01
CN1915231A (zh) 2007-02-21
US7129270B2 (en) 2006-10-31
NO20030406L (no) 2003-03-27
HUP0301344A3 (en) 2004-10-28
PL366336A1 (en) 2005-01-24
EP1309571A1 (de) 2003-05-14
YU5503A (sh) 2006-05-25
TWI282336B (en) 2007-06-11
HRP20030148A2 (en) 2005-10-31
NZ523822A (en) 2006-01-27
BG107488A (bg) 2003-07-31
EA200300105A1 (ru) 2003-06-26
CA2417444A1 (en) 2002-02-07
SK812003A3 (en) 2003-07-01
IL154143A0 (en) 2003-07-31
CN1444570A (zh) 2003-09-24
KR20030019626A (ko) 2003-03-06
EE200300043A (et) 2004-10-15

Similar Documents

Publication Publication Date Title
JP2004505068A (ja) 非ステロイド性抗炎症剤
KR100762058B1 (ko) 비스테로이드성 항염증제
JP2006512382A (ja) 非ステロイド性抗炎症剤
JP4460608B2 (ja) ５−置換キノリンおよびイソキノリン誘導体、それらの製造方法および抗炎症剤としてのそれらの使用
JP2014530184A (ja) Ｅｐ１受容体のリガンド
US7112584B2 (en) Nonsteroidal antiinflammatory agents
JP4762551B2 (ja) インデノンカルボン酸誘導体ならびに糖尿病および脂質代謝異常を治療および予防するためのそれらの使用
WO2002053550A1 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
JPH09124631A (ja) ベンゾフラン誘導体及びそれを含む医薬組成物
WO2004113344A1 (ja) ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法
CN115160285A (zh) 硫代酰胺类aldh2激动剂、制备方法及应用
JPWO2000023442A1 (ja) カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
JPWO1999015520A1 (ja) 縮合または非縮合ベンゼン化合物
HK1201269B (en) Ep1 receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080722

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091030